This inventor holds 4 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 2 EPO patents. Top assignee: Aprea Ab. Active years: 2005-2010.
Location History:
- Solna, SE (2005 - 2010)
- Solona, SE (2010)
Company Filing History:
Years Active: 2005-2010
Title: Galina Selivanova: Innovator in Pharmaceutical Chemistry
Introduction
Galina Selivanova is a prominent inventor based in Solna, Sweden. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for treating various diseases. With a total of 4 patents to her name, her work focuses on innovative solutions for complex medical challenges.
Latest Patents
Selivanova's latest patents include groundbreaking research on Azabicyclooctan-3-one derivatives and their applications. These compounds are designed for use in pharmaceutical compositions aimed at treating hyperproliferative diseases, such as cancer, autoimmune diseases, and heart disease. Another notable invention involves low molecular weight compounds that reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is crucial for restoring the sequence-specific DNA-binding activity and transcriptional transactivation function of these proteins, which can lead to effective treatments for various types of tumors.
Career Highlights
Galina Selivanova is currently associated with Aprea AB, a company dedicated to advancing cancer therapies. Her work has been instrumental in developing innovative treatments that address significant medical needs. Her research has garnered attention for its potential impact on patient care and treatment outcomes.
Collaborations
Selivanova has collaborated with notable professionals in her field, including Vladimir Bykov and Klas Wiman. These partnerships have enhanced her research efforts and contributed to the advancement of her innovative projects.
Conclusion
Galina Selivanova stands out as a leading inventor in pharmaceutical chemistry, with a focus on developing novel treatments for serious diseases. Her contributions through her patents and collaborations highlight her commitment to improving healthcare outcomes.